BIOVIC B Share Price Performance
SEK 0.50
-0.16 (-24.01%)
72.2% undervalued intrinsic discount
SEK 1.80
Fair Value
Price SEK 0.50
AnalystHighTarget SEK 1.80
AnalystConsensusTarget SEK 0.60
AnalystLowTarget SEK 0.60
Fair ValueSEK 1.80
Share Pricen/a
Biovica International AB (publ) Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
BIOVIC B Community Narratives
AN
Fair Value
·Fair Value SEK 1.8 72.2% undervalued intrinsic discount
Growing Cancer Incidence And AI Will Drive Diagnostic Expansion
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value SEK 0.6 16.7% undervalued intrinsic discount
Profitability Outlook Will Adjust Despite Stable Revenue And Equity Raise
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value SEK 0.6 16.7% undervalued intrinsic discount
Rising Reimbursement Cuts And Delays Will Weaken Market Prospects
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Profitability Outlook Will Adjust Despite Stable Revenue And Equity Raise
Biovica is trying to turn its cancer blood test into a more widely used tool in breast cancer care, helped by new study results and deals with big healthcare and distribution partners. The upside hinges on those partnerships translating into real hospital adoption before the company runs short on cash and while it still needs additional approvals for a larger part of the market.Read more
AN
SEK 0.6
16.7% undervalued intrinsic discount
Fair Value
Profit Margin
20.95%
Future PE
16.42x
Price in 2029
SEK 0.39
Growing Cancer Incidence And AI Will Drive Diagnostic Expansion
Key Takeaways Success in clinical trials and partnerships could accelerate adoption of DiviTum, driving rapid sales growth, recurring revenues, and higher gross margins through scalability and digital integration. Biovica's unique diagnostic position in value-based healthcare and precision oncology enhances its potential for durable premium pricing, industry consolidation, and attractiveness as an acquisition target.Read more
AN
SEK 1.8
72.2% undervalued intrinsic discount
Fair Value
Profit Margin
17.97%
Future PE
44.32x
Price in 2029
SEK 1.17
Rising Reimbursement Cuts And Delays Will Weaken Market Prospects
Key Takeaways Heavy dependence on a single product and regulatory setbacks threaten Biovica's competitive edge, revenue growth, and earnings visibility. Increased cost containment, supply chain disruptions, and fierce competition limit pricing power and depress profitability.Read more
AN
SEK 0.6
16.7% undervalued intrinsic discount
Fair Value
Profit Margin
21.33%
Future PE
3.18x
Price in 2028
SEK 1.54
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
BIOVIC B: Future Upside Will Hinge On Metastatic Breast Cancer Monitoring
Fair Value: SEK 0.6 16.7% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
BIOVIC B: Expanded U.S. Cancer Center Use Will Support Future Test Adoption
Fair Value: SEK 1.8 72.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Reimbursement Cuts And Delays Will Weaken Market Prospects
Fair Value: SEK 0.6 16.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Biovica International AB (publ) Key Details
Last Reported Earnings
Apr 30, 2026
Next Reporting Earnings
Sep 10, 2026
- -0.24
- 99.68%
- -518.06%
- 0%
About BIOVIC B
- Founded
- 2008
- Employees
- 25
- CEO
- WebsiteView website
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
